CBG for Glaucoma: Revisiting an Old Discovery

Long before CBD became a wellness buzzword and THC was dissected for its psychoactive effects, scientists in the 1970s were quietly studying another cannabinoid — CBG, or cannabigerol. Often called the “mother of all cannabinoids,” CBG is the precursor from which THC, CBD, and many others are synthesized inside the cannabis plant.

But what’s old is new again. Early experiments hinted that CBG could lower intraocular pressure (IOP) — the main culprit in glaucoma, a leading cause of irreversible blindness. Back then, the spotlight fell on THC for doing the same, but its psychoactive effects made it impractical as a long-term treatment. CBG, with its non-intoxicating profile, was largely forgotten — until now.

Today, researchers are revisiting those early findings with new tools and technologies. Could CBG offer the pressure-lowering benefits of THC without the high? And might it even protect the optic nerve itself? Let’s take a look at what modern science says about this rediscovered cannabinoid and its potential for eye health.

Understanding Glaucoma and Intraocular Pressure (IOP)

Glaucoma isn’t just one disease — it’s a group of conditions that share a common problem: damage to the optic nerve, often linked to elevated intraocular pressure (IOP). The optic nerve acts like a cable connecting the eye to the brain; when it’s under constant pressure, fibers gradually die, leading to blind spots and, eventually, vision loss.

How Eye Pressure Works

Inside the eye, a clear fluid called aqueous humor circulates continuously — it nourishes tissues and maintains the shape of the eyeball. The fluid is produced by the ciliary body and drains through a delicate meshwork of channels near the cornea.

When this outflow system gets blocked or the eye produces too much fluid, pressure builds up. Think of it like a sink where the faucet runs faster than the drain. Over time, that extra pressure damages the optic nerve fibers.

Current Treatments and Their Limits

Traditional glaucoma therapies focus on reducing IOP — either by slowing fluid production (using beta-blockers, carbonic anhydrase inhibitors) or by improving drainage (with prostaglandin analogs). These drugs help but come with drawbacks:

• Tolerance can develop over time, reducing effectiveness.
• Some cause irritation, redness, or changes in eye color.
• They don’t address neurodegeneration — the progressive loss of nerve tissue.

That’s where cannabinoids re-enter the picture. They don’t just modify pressure — they may also influence neuroprotection and blood flow, opening a new therapeutic window for glaucoma care.

Endocannabinoid System and the Eye

The endocannabinoid system (ECS) is one of the body’s master regulators, fine-tuning processes like pain perception, mood, and immune response. What many people don’t realize is that it also plays a vital role in eye physiology — particularly in how intraocular pressure is maintained and how retinal cells communicate.

Where Cannabinoid Receptors Live in the Eye

• CB1 receptors are abundant in the ciliary body, iris, and trabecular meshwork — the very structures responsible for producing and draining aqueous humor.
• CB2 receptors are found mainly in immune and glial cells of the retina, where they help modulate inflammation and protect neurons from oxidative stress.
• Enzymes that build and break down endocannabinoids, like FAAH and MAGL, are also active in ocular tissue.

This means the ECS is hardwired into the eye’s internal pressure control system.

How the ECS Regulates Eye Pressure

When CB1 receptors are stimulated, they can:

• Reduce fluid production from the ciliary body.
• Increase outflow of aqueous humor through the trabecular meshwork.
• Improve ocular blood flow, delivering oxygen and nutrients to the optic nerve.

Meanwhile, activation of CB2 receptors appears to calm inflammation and may protect retinal ganglion cells — the neurons that carry visual signals to the brain.

The Cannabinoid Connection

Cannabinoids like THC and CBG can mimic or modulate these natural pathways, leading to temporary decreases in intraocular pressure. The key challenge is sustaining that benefit without unwanted psychoactive effects — which is where CBG begins to stand out.

What We Know About CBG’s Mechanism of Action

CBG might not be the most famous cannabinoid, but in the eye, it behaves like a skilled multitasker — gently influencing several biological systems at once. Unlike THC, which powerfully activates CB1 receptors, CBG interacts more selectively and moderately, leading to pressure-lowering effects without intoxication.

Multi-Target Modulation

CBG’s mechanism of action is complex but fascinating:

• CB1 and CB2 modulation: CBG partially binds to both, supporting fluid drainage and protecting ocular neurons.
• α2-Adrenergic receptor activation: This receptor is also a target for many standard glaucoma medications (like brimonidine). When CBG stimulates it, it helps reduce aqueous humor production and improves ocular blood flow.
• TRP channel activity: CBG influences transient receptor potential channels (TRPV1, TRPA1), which may further support anti-inflammatory and vasodilatory effects.

Beyond Pressure Control: Neuroprotection

Glaucoma isn’t just about pressure; it’s also about nerve damage. CBG shows early evidence of neuroprotective potential:

• It may reduce oxidative stress in retinal cells.
• It can decrease glutamate toxicity, a major cause of neuron death in glaucoma.
• Animal studies suggest improved retinal survival when CBG is administered after ischemic injury (blood flow restriction).

Why It Stands Out

Because CBG doesn’t overstimulate CB1 receptors, it doesn’t trigger euphoria, red eyes, or anxiety — side effects often associated with THC-based glaucoma therapies. This makes it a promising candidate for long-term management rather than short-term relief.

In short: CBG works not by blasting receptors open but by fine-tuning multiple systems involved in eye pressure and nerve health — a gentler, smarter approach that modern pharmacology is finally beginning to appreciate.

Research Evidence: Then and Now

Interest in cannabinoids for glaucoma isn’t new — it started half a century ago. But while THC got most of the attention (and controversy), CBG quietly showed promise in early lab work that has recently come full circle.

The 1970s: The First Clues

In 1975, one of the earliest studies on cannabinoids and glaucoma (Hepler & Frank, Journal of Clinical Pharmacology) noted that not only THC but also lesser-known compounds like CBG and CBD could lower intraocular pressure in animal models. At the time, researchers lacked tools to study receptor mechanisms, but they observed a clear trend — pressure dropped within hours of cannabinoid administration.

Those findings were overshadowed when THC became the star of the show — but its short duration of action (3–4 hours) and psychoactive effects made it impractical as a long-term treatment. CBG was shelved, waiting for science to catch up.

The 2000s–2010s: Rediscovery Through the ECS

As researchers uncovered the endocannabinoid system and mapped CB1/CB2 receptors in the eye, CBG returned to focus.

• In 2000, Colasanti et al. showed that CBG reduced IOP in cats without inducing behavioral side effects.
• Follow-up studies suggested that CBG’s pressure-lowering effect could persist longer than THC, possibly due to its alpha-2 receptor activity.
• In 2013, in vitro tests demonstrated that CBG could protect retinal ganglion cells from oxidative stress — hinting at a neuroprotective layer of benefit.

The 2020s: Modern Insights

Recent preclinical studies have deepened the understanding:

• CBG enhances ocular blood flow and decreases inflammation in experimental glaucoma models (Bodor et al., 2021).
• Early animal data indicate that CBG+CBD combinations offer stronger protection for retinal cells than either alone, suggesting a synergistic “entourage effect.”
• However, large-scale human clinical trials are still missing. Current research mostly involves topical or oral formulations being tested for bioavailability and safety.

The conclusion from five decades of research is clear: CBG consistently lowers intraocular pressure and may protect vision, but its clinical translation is still at an early stage.

Comparison with THC and Conventional Treatments

THC proved decades ago that cannabinoids can lower eye pressure, but its short action window and psychoactive effects limit real world use. CBG aims for similar IOP benefits with fewer trade offs.

THC vs CBG for IOP

Onset and duration

• THC: fast onset, effect often fades in 3–4 hours.
• CBG: preclinical data suggest steadier, potentially longer pressure control.

Side effects

• THC: euphoria, impaired focus, tachycardia, red eyes.
• CBG: non intoxicating profile, milder systemic effects in animal studies.

Mechanism emphasis

• THC: strong CB1 agonism.
• CBG: multimodal action — moderate CB1/CB2 plus α2 adrenergic and TRP channels.

How CBG Might Fit Alongside Standard Therapy

With prostaglandin analogs

First line drops increase uveoscleral outflow. CBG could complement by supporting trabecular outflow and reducing aqueous production.

With beta blockers or carbonic anhydrase inhibitors

These reduce fluid formation. CBG’s α2 like activity may add a gentle extra brake without overlapping side effects seen with systemic agents.

Neuroprotection angle

Standard IOP lowering drugs do not directly protect retinal ganglion cells. CBG’s antioxidant and anti inflammatory signals suggest a potential adjunct role for optic nerve health.

Reality check

• Conventional drops are clinically proven to slow glaucoma progression.
• CBG currently sits in the adjunct and investigational category. Until human trials show equivalence or clear additive benefit, it should be viewed as a complement, not a replacement.

Safety, Delivery, and Clinical Perspectives

CBG looks promising for lowering intraocular pressure, but translating lab signals into real-world therapy requires careful attention to safety, dose form, and clinical monitoring.

Delivery Routes

Topical (eye drops, gels)

• Pros: targets the eye directly, minimizes systemic exposure.
• Cons: cannabinoids are lipophilic and penetrate the cornea poorly without the right carriers. Formulation tech matters. Look for emulsions, micelles, or lipid nanoparticles designed for ocular use.

Oral (oils, capsules)

• Pros: easy to use, steady systemic levels.
• Cons: variable absorption, first pass metabolism, and less predictable impact on IOP compared with well designed drops.

Sublingual/oromucosal

• Pros: faster onset than standard oral, bypasses some first pass metabolism.
• Cons: still systemic, not eye targeted.

Inhaled

• Not recommended for glaucoma management. Short duration, systemic exposure, and no ocular targeting.

Formulation Considerations

• Bioavailability is the bottleneck. Effective ocular CBG likely needs advanced carriers (cyclodextrins, nanoemulsions, liposomes).
• Stability matters. Protect from light, heat, and oxidation to preserve potency.
• Preservatives in eye drops can irritate. Benzalkonium chloride free or low preservative designs are preferable for chronic use.

Dosing and Monitoring (Investigational Context)

• Start with topical if available, once or twice daily, and reassess with IOP measurements.
• If using oral CBG adjunctively, begin low and titrate cautiously.
• Track outcomes: IOP at baseline and follow up, symptoms, visual fields, optic nerve imaging where applicable.
• Any change in therapy should be coordinated with an ophthalmologist.

Potential Side Effects

• Topical: transient stinging, redness, blurred vision from the vehicle, rare allergic irritation.
• Systemic: fatigue, dry mouth, GI upset. CBG is non intoxicating, but individual sensitivities vary.
• Ocular surface: watch for dryness or irritation with chronic preservatives.

Drug Interactions and Precautions

• Cannabinoids can interact with hepatic enzymes (CYP pathways). If taking systemic CBG, review concomitant meds with a clinician.
• Combine cautiously with other IOP lowering drops. Avoid unsupervised substitution of proven therapy.
• Special populations: pregnancy, severe cardiovascular disease, or history of ocular surgery require clinician oversight.

Regulatory and Clinical Status

• Conventional agents (prostaglandins, beta blockers, CAIs, α2 agonists) remain first line with robust evidence for slowing glaucoma progression.
• CBG for glaucoma is investigational. It should be considered an adjunct within a supervised treatment plan until controlled human trials define efficacy, dose, and long term safety.

Conclusion: Rediscovering a Promising Ally for Eye Health

CBG is not new, but our understanding of it is. Early observations that cannabinoids can lower intraocular pressure have been refined by modern insights into the endocannabinoid system, showing plausible pathways for CBG to reduce aqueous humor production, enhance outflow, and potentially protect retinal ganglion cells.

What we have now is a consistent preclinical signal and historical hints, plus formulation advances that could make ocular delivery feasible. What we still lack are rigorous human trials that define real-world efficacy, optimal dosing, duration of effect, and long-term safety.

Until those data arrive, CBG belongs in the adjunct and investigational category. It should complement, not replace, proven glaucoma therapies and always be used under ophthalmologic supervision with objective monitoring of intraocular pressure and visual function.

If ongoing research confirms both pressure control and neuroprotection, CBG could evolve from a rediscovered curiosity into a meaningful addition to the glaucoma toolkit. For now, cautious optimism and clinical prudence are the right lens.